Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Inclusion Criteria: Histologically confirmed non-small cell lung cancer Stage IIIB or IV disease Radiographically measurable disease 18 and over Performance status: ECOG 0-2 Renal: Creatinine ≤ 2 mg/dL Negative pregnancy test Fertile patients must use effective contraception More than 4 weeks since prior chemotherapy Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent corticosteroids, including chronic corticosteroids, except for medically-indicated topical steroids Radiotherapy: More than 4 weeks since prior radiotherapy More than 4 weeks since other prior anticancer therapy More than 4 weeks since prior non-cytotoxic investigational agents At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs) Exclusion Criteria: pregnant or nursing comorbid disease, psychiatric condition, chronic medical condition, or laboratory abnormality that would preclude study treatment or compliance with study requirements hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study reagent history of gastrointestinal ulceration, bleeding, or perforation other concurrent cyclooxygenase-2 or -3 inhibitors other concurrent NSAIDs